ATT safe in hepatic failure are :
**Core Concept**
The question tests knowledge of antitubercular treatment (ATT) safety in patients with hepatic failure, focusing on **hepatotoxicity** and **liver function**. ATT drugs can be **hepatotoxic**, making liver function monitoring crucial.
**Why the Correct Answer is Right**
Although the correct answer is not specified, generally, **rifampicin**, **isoniazid**, and **pyrazinamide** are known to be hepatotoxic. In hepatic failure, **streptomycin** and **ethambutol** are considered safer options as they are less hepatotoxic.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific answer choices, it's challenging to provide detailed incorrect option analysis. However, typically, options including **rifampicin** or **pyrazinamide** would be incorrect due to their hepatotoxic potential.
**Clinical Pearl / High-Yield Fact**
In patients with hepatic failure, it's crucial to choose **ATT** drugs wisely to avoid exacerbating liver damage. Monitoring **liver function tests** is essential when initiating ATT in such patients.
**Correct Answer:** Not provided in the query.